



IWGDF Guidance – Disclosure of interest form

Name: Catherine Gooday

Affiliation: Norfolk & Norwich University Hospitals NHS Foundation Trust

Position: Principal Podiatrist, NIHR Clinical Doctoral Fellow.

IWGDF Working Group: Offloading 2019

For the following items, please disclose any interest from the past five years that might be perceived by others as potentially influencing your judgment in any topic in the IWGDF Guidance that you contribute to.

- Ancillary positions:

1. Member of the Guideline Development Group for; Diabetic foot problems: prevention and management NICE guidelines [NG19] Published: August 2015
<https://www.nice.org.uk/guidance/ng19>
2. Expert Adviser for the NICE Centre for Guidelines (CfG) - October 2016 – 2019
3. Member of the National Diabetes Audit (NDA) Partnership Board and the National Diabetes Foot Audit Advisory Group

- Personal financial interests (this includes personal financial interests such as stocks and shares, personally receiving finances, or receiving funding for an account that you benefit from financially or professionally):

N/A

- Personal relations (this includes personal relations or relations via close family that might be perceived by others as potentially influencing your judgment):

N/A

- Externally funded research (this includes research funding awarded to you as project member, or to your department, for funding that might be perceived by others as potentially influencing your judgment):

Fellowship funding

1. National Institute Health Research, Clinical Doctoral Fellowship (ICA-CDRF-2015-01-050)

The department in which I work has or is currently taken part in the following funded research activities

1. A prospective, open, non-controlled clinical investigation to evaluate the Avance™ NPWT System, a new negative pressure wound therapy (NPWT) system to be used in the treatment of diabetic foot ulcers (DFUs) and post amputation wounds following DFU.

2. Evaluation of lightweight fibreglass heel casts in the management of heel ulcers in diabetes.
3. Comparing sampling methods in diabetic foot infections (CODIFI).
4. An open, non-comparative, multi-centre post marketing clinical follow up (PMCF) investigation to evaluate the performance and safety on Diabetic Foot Ulcer DFU, when using Mepilex Transfer AG as intended.
5. Assessment of the efficacy and safety of a new wound dressing in the local treatment of diabetic foot ulcers (EXPLORER).
6. A randomised, double blind, placebo controlled multicentre trial, examining the effect of Natrox™ on the rates of healing for chronic diabetic foot ulcers (TODFU2).
7. Leucopatch® in the management of hard-to-heal Diabetic Foot Ulcers.
8. A phase 1b, blinded, randomised, multicentre, multiple-ascending dose study of the safety, tolerability pharmacokinetic of UTTR1147A administered by subcutaneous injection in patients with non-healing neuropathic diabetic foot ulcers.
9. Assessment of the efficacy and safety of a new medical device in the local treatment of diabetic foot ulcers (DFUs): a prospective, randomized, controlled, double-blind, European, multicentre clinical trial (DISCOVERY).
10. Multiple Interventions of Diabetic Foot Ulcer Treatment Trial (MIDFUT)

- Other disclosures:

N/A

When you have nothing to declare, please state here:

Signature and date:

A handwritten signature in black ink that reads "omgooday". The signature is written in a cursive, lowercase style.

30th July 2018